Disclosed is the use of a compound of formula I (eg (S)-3-[ 4-( 4-morphlin-4-ylmethylbenzyloxy)-I-oxo-l ,3-dihydro-isoindo-2-yl]piperidine-2,6-dione) or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof, in manufacturing a medicament for treating, preventing or managing an immune-related disease or an inflammatory disease, or a symptom thereof, in a patient in need thereof, wherein the disease is systemic lupus erythematosus, cutaneous lupus erythematosus, scleroderma, lupus pernio, sarcoidosis, Sjögren syndrome, ANCA-induced vasculitis, anti-phospholipid syndrome or myasthenia gravis.
